BTK and B-cell non-Hodgkin lymphoma: Recently, several drugs targeting BCR signal, especially the Btk inhibitor ibrutinib (PCI-32765), have clearly demonstrated promising therapeutic effects in relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (B-NHL) [5-7].